This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Colchicine | |
|---|---|
| Name | Colchicine |
| Tradename | Colcrys, Mitigare, Gloperba |
| Routes of administration | Oral, intravenous (investigational) |
| Class | Antimitotic, anti-inflammatory |
| Legal status | Prescription-only |
| Pregnancy category | Not recommended |
Colchicine is an alkaloid originally isolated from the autumn crocus that is used primarily for the treatment of gout and familial Mediterranean fever. It has a narrow therapeutic index and an established role in rheumatology, internal medicine, and emergency care, and it has been the subject of studies in cardiology, oncology, and infectious disease. High-profile figures in pharmacognosy and medicine promoted its clinical adoption during the 19th and 20th centuries, and regulatory decisions by agencies shaped its modern availability.
Colchicine is indicated for acute gout flares and prophylaxis in patients with recurrent gout, and for periodic fever syndromes such as familial Mediterranean fever, with guideline endorsement from organizations like the American College of Rheumatology and the European League Against Rheumatism. In cardiology, randomized trials and meta-analyses involving institutions such as the Colchicine Cardiovascular Outcomes Trial investigators examined its role after myocardial infarction and in pericarditis with involvement from centers associated with the European Society of Cardiology and the American Heart Association. Research in oncology centers including Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center explored colchicine’s antimitotic effects on microtubules in malignancies studied at meetings of the American Society of Clinical Oncology and the European Society for Medical Oncology. In infectious disease, investigators at the National Institutes of Health and the World Health Organization reviewed colchicine in COVID-19 trials sponsored by academic centers in Canada and Europe. Pediatric use for hereditary periodic fever syndromes has been described in literature from children’s hospitals such as Great Ormond Street Hospital and Boston Children’s Hospital.
Colchicine exerts its effects by binding to tubulin and inhibiting microtubule polymerization, a mechanism elucidated in biochemical studies at institutions like the Max Planck Institute and Cold Spring Harbor Laboratory. This disrupts intracellular trafficking and inflammasome activation pathways characterized by work from researchers at Harvard Medical School and the Pasteur Institute, reducing interleukin-1β processing described in publications from the National Institute of Allergy and Infectious Diseases. Cellular studies from laboratories at Johns Hopkins University and the Karolinska Institutet detailed impacts on neutrophil chemotaxis and adhesion molecules, while structural insights were contributed by crystallography groups at the European Molecular Biology Laboratory and the Royal Society of Chemistry.
Colchicine is classified pharmacologically as an antimitotic alkaloid with anti-inflammatory properties, a classification codified in formularies from the United States Pharmacopeia and the British Pharmacopoeia. Its dose-response relationships were characterized in pharmacology departments at University College London and the University of California, San Francisco, and pharmacodynamic interactions with drugs metabolized by cytochrome P450 3A4 and transported by P-glycoprotein were delineated in studies from the Food and Drug Administration and the European Medicines Agency. Clinical pharmacologists at the Mayo Clinic and Cleveland Clinic contributed to understanding therapeutic regimens, while pharmacovigilance reports from the World Health Organization Uppsala Monitoring Centre and the Institute for Safe Medication Practices informed risk mitigation strategies.
Common adverse effects include gastrointestinal symptoms such as diarrhea, nausea, and vomiting, reported in clinical trials conducted at centers like Mount Sinai Hospital and Karolinska University Hospital. Hematologic effects including neutropenia and thrombocytopenia were documented in case series from oncology units at Memorial Sloan Kettering and The Royal Marsden Hospital. Neuromuscular toxicity, manifesting as myopathy and neuropathy, was described in neurology case reports from Johns Hopkins and University of Oxford clinics, often occurring in patients receiving concomitant statins or macrolide antibiotics reviewed by agencies such as the European Medicines Agency. Dermatologic and hepatic abnormalities were reported in pharmacovigilance summaries by the Medicines and Healthcare products Regulatory Agency and Health Canada.
Acute colchicine poisoning produces a well-recognized clinical progression described in toxicology texts from Yale School of Medicine and St. Thomas’ Hospital, including an initial gastrointestinal phase, a multisystem organ failure phase, and possible recovery with alopecia in survivors. Lethal outcomes were documented in forensic studies from coroners’ offices in Paris, New York City, and Toronto, prompting warnings from poison control centers like the American Association of Poison Control Centers and the National Poisons Information Service. Management protocols from critical care societies including the Society of Critical Care Medicine and the European Society of Intensive Care Medicine emphasize supportive care, activated charcoal administration, and consideration of investigational therapies such as colchicine-specific Fab fragments developed in academic-industry collaborations at biotech firms and university spinouts.
Pharmacokinetic parameters were defined in clinical pharmacology trials at institutions such as Vanderbilt University and the University of Michigan, showing oral bioavailability with variable absorption, widespread tissue distribution including leukocytes and renal tissue, hepatic metabolism involving CYP3A4, and biliary and renal excretion. Dose adjustments in renal impairment were recommended in guidance from the National Kidney Foundation and nephrology units at Columbia University and the Royal Free Hospital. Drug interaction warnings regarding macrolides, azole antifungals, protease inhibitors, and calcium channel blockers were emphasized in labeling by regulatory authorities including the FDA and EMA.
Colchicine’s therapeutic use traces to ancient descriptions by physicians in Hellenistic Alexandria and medieval Byzantine texts, later isolated chemically in the 19th century by phytochemists at the University of Montpellier and the University of Geneva. The drug’s commercial development involved pharmaceutical companies such as GlaxoSmithKline and Rottapharm and regulatory submissions to bodies including the FDA and EMA, with patent litigation and access debates reported in legal journals and mainstream media outlets like The New York Times and The Guardian. Its societal impact includes roles in public health guidance from the Centers for Disease Control and Prevention and inclusion on hospital formularies across academic medical centers such as Massachusetts General Hospital and Guy’s and St Thomas’ NHS Foundation Trust. Ongoing research at universities including Stanford University and the University of Cambridge continues to explore new indications and to inform policy discussions involving health technology assessment agencies like NICE and CADTH.
Category:Alkaloids Category:Anti-inflammatory agents Category:Rheumatology drugs